Yutaka Kanda

This inventor holds 64 USPTO granted patents and 1 published patent application, plus 4 CIPO patents and 11 EPO patents, primarily in Antibody Engineering (CPC class C07K). Top assignees: Kyowa Hakko Kirin Co., Limited, Kyowa Hakko Kogyo Co., Ltd., Kyowa Hakko Kogyo Kabushiki Kaisha. Active years: 1989-2019.

USPTO Granted Patents = 64 (Patent Applications = 1)

% Patents Active = 48.4

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 11 (Patent Applications = 3)

Average Co-Inventor Count = 7.2

ph-index = 19

Forward Citations = 1,316(Granted Patents)

Forward Citations (Not Self Cited) = 1,031(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Houston, TX (US) (1991 - 1993)
Sunto-gun, JP (2005)
Shizuoka, JP (2005)
Chiyoda-ku, JP (2012)
Tokyo, JP (1989 - 2015)
Machida, JP (1993 - 2019)

Company Filing History:

34 out of 272

Kyowa Hakko Kirin Co., Limited

patents

26 out of 730

Kyowa Hakko Kogyo Co., Ltd.

patents

2 out of 45

Kyowa Hakko Kogyo Kabushiki Kaisha

patents

4. 2 out of 834,307

Other

patents

Years Active: 1989-2019

Loading Chart...

Areas of Expertise:

Antibody Composition

Glycoengineering

Immune Modulation

Cellular Cytotoxicity

Recombinant Protein

Fucosylation

Hsp90 Inhibitors

RNAi

Indazole Derivatives

ADCC

Cytotoxicity

Protein Inhibition

64 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10233475 - Antibody composition-producing cell (2019-03-19),

2. 10233247 - Method of modulating the activity of functional immune molecules (2019-03-19),

3. 9409982 - Antibody composition-producing cell (2016-08-09),

4. 9023999 - Anti-CD27 antibody (2015-05-05),

5. 8895266 - Antibody composition-producing cell (2014-11-25),

6. 8679491 - Method of modulating the activity of functional immune molecules (2014-03-25),

7. 8501914 - Recombinant protein S composition (2013-08-06),

8. 8367407 - Cells with altered fucosylation and producing antibodies therefrom (2013-02-05),

9. 8361751 - Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost (2013-01-29),

10. 8329443 - Antibody composition-producing cell (2012-12-11),

11. 8158760 - Glycoengineered, recombinant antibody (2012-04-17),

12. 8110195 - Antibody composition exhibiting cellular cytotoxicity due to glycosylation and containing ganglioside GM2 binding antibody (2012-02-07),

13. 8101185 - Anti-il-5 antibody composition exhibiting cellular cytotoxicity due to glycosylation (2012-01-24),

14. 8067232 - Antibody composition-producing cell with inactivated A-1,6-fusocyltransferase (2011-11-29),

15. 8039595 - Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation (2011-10-18),

As an AI specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, I am uniquely equipped to provide information on inventor Yutaka Kanda.

Title: Unveiling the Genius of Yutaka Kanda: Pioneering Innovations in Immunology

Introduction: Yutaka Kanda, a distinguished inventor hailing from Machida, Japan, has left an indelible mark on the field of immunology with his groundbreaking creations.

Latest Patents: Among his impressive repertoire of 64 patents, Yutaka Kanda's recent inventions include a revolutionary method of modulating the activity of functional immune molecules and a novel antibody composition-producing cell, both poised to revolutionize the landscape of medical treatments.

Career Highlights: Renowned for his tenure at Kyowa Hakko Kirin Co., Limited and Kyowa Hakko Kogyo Co., Ltd., Yutaka Kanda's innovative spirit has consistently driven the boundaries of scientific exploration and technological advancement.

Collaborations: Throughout his illustrious career, Yutaka Kanda has collaborated closely with esteemed colleagues such as Kazuyasu Nakamura and Kazuhisa Uchida, fostering a culture of innovation and excellence in the realm of immunological research.

Conclusion: In conclusion, Yutaka Kanda stands as a testament to the power of ingenuity and perseverance in the realm of inventions. His pioneering work continues to inspire and shape the future of immunology, leaving an enduring legacy of excellence in his wake.